Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.58 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR5A | P47898 | 2/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.53 |
| ▸ | HTR3B | O95264 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20139829 | 0.98 | ADRB1 (0.56) | ADRB1HTR6HTR7HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL29882725 | 0.98 | ADRB1 (0.56) | ADRB1HTR6HTR7HTR1AHTR2A | |
| SCHEMBL20140127 | 0.93 | ADRB1 (0.51) | ADRB1HTR6HTR7HTR1AHTR2A | |
| SCHEMBL6718397 | 0.89 | DRD2 (0.53) | ADRB1HTR6HTR7HTR1AHTR2A | |
| SCHEMBL232795 | 0.86 | ALDH1A1 (0.53) | ADRB1HTR6HTR7HTR1AHTR2A | |
| SCHEMBL3088832 | 0.86 | DRD4 (0.54) | HTR7HTR1AALDH1A1DRD2DRD3 | |
| SCHEMBL2341786 | 0.85 | HTR2A (0.44) | ADRB1HTR6HTR7HTR1AHTR2A | |
| SCHEMBL25003058 | 0.84 | DRD2 (0.63) | ADRB1HTR6HTR7HTR1AHTR2A | |
| SCHEMBL30839756 | 0.84 | DRD2 (0.63) | ADRB1HTR6HTR7HTR1AHTR2A | |
| SCHEMBL26968319 | 0.84 | ALDH1A1 (0.52) | ADRB1HTR6HTR7HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | FUTURE MEDICINE CO., LTD. (KR) | 2024-06-20 | — | — | US | claimed |
| EP-4296273-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | Future Medicine Co., Ltd. (KR) | 2023-12-27 | — | — | EP | claimed |
| CN-117083286-A | Pair A 2A A is a 3 Adenosine derivatives having antagonism to adenosine receptor and process for preparing same | 未来制药有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-116444454-B | N-hydroxy amidine derivative, preparation method and application thereof, and tumor immunotherapy medicament | 中国医学科学院医药生物技术研究所 | 2023-09-12 | — | — | CN | claimed |
| CN-116444454-A | N-hydroxy amidine derivative, preparation method and application thereof, and tumor immunotherapy medicament | 中国医学科学院医药生物技术研究所 | 2023-07-18 | — | — | CN | claimed |
| WO-2022203427-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | 퓨쳐메디신 주식회사 | 2022-09-29 | — | — | WO | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| CN-102807577-B | Chiral compound | LUO MEI | 2015-04-22 | — | — | CN | claimed |
| CN-101795689-B | Positive allosteric modulators of benzamide mGluR5 and methods of making and using the same | UNIV VANDERBILT | 2014-11-19 | — | — | CN | claimed |
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | claimed |
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | claimed |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | claimed |
| US-20110207739-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | claimed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | claimed |
| EP-2051978-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | claimed |
| JP-2008521903-A | — | — | 2008-06-26 | — | — | JP | claimed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207739-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | ANXA1, ANXA5, ANXA2 | ADRB1 2309/4885HTR6 3434/4885HTR7 4309/4885 |
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | ADORA2A, ADORA3, ADORA2B | ADRB1 39/4885HTR6 55/4885HTR7 42/4885 |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | ADRB1 3656/4885HTR6 3700/4885HTR7 2326/4885 |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | TERT, ACIN1, AK2 | ADRB1 2807/4885HTR6 3475/4885HTR7 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.